Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999868 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT01999868 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 108 participants.
The verdict
NCT01999868, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the use of ustekinumab, followed by abatacept, will prevent relapse in people with moderate to severe plaque psoriasis.
Interventions
- BIOLOGICAL Abatacept
- BIOLOGICAL Ustekinumab
- DRUG UST Placebo
- DRUG ABA Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2014-03-19 |
| Est. Completion | 2018-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999868
The ClinicalTrials.gov registry entry for NCT01999868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Abatacept is the first listed.
NCT01999868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999868 about?
NCT01999868 is a clinical study titled "Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris". The purpose of this study is to determine if the use of ustekinumab, followed by abatacept, will prevent relapse in people with moderate to severe plaque psoriasis.
What is the current status of trial NCT01999868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2014-03-19. Estimated completion is 2018-03-01.
What interventions are being tested in trial NCT01999868?
The interventions under investigation include: Abatacept (BIOLOGICAL), Ustekinumab (BIOLOGICAL), UST Placebo (DRUG), ABA Placebo (DRUG).
Who is sponsoring clinical trial NCT01999868?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.